Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating

Needham analyst Joseph Stringer has maintained their bullish stance on GILD stock, giving a Buy rating on October 2.

Joseph Stringer has given his Buy rating due to a combination of factors related to Gilead Sciences’ strategic initiatives and future growth potential. One of the key reasons is the company’s promising inflammation pipeline, which, despite being in the early stages, is seen as a crucial element for Gilead’s long-term diversification strategy beyond its traditional focus on HIV and oncology. This pipeline is expected to become more significant over time and could act as a commercial bridge before the loss of exclusivity of Biktarvy in 2033.
Furthermore, Stringer anticipates that Gilead might enhance its business development activities, particularly focusing on earlier-stage assets to bolster its pipeline. The most notable assets in this pipeline include edecesertib for lupus, GS-1427 and tilpisertib fosmecarbil for inflammatory bowel disease, and a preclinical oral STAT6 program. These developments suggest a strong potential for future growth, justifying the Buy rating.

In another report released on October 2, Morgan Stanley also reiterated a Buy rating on the stock with a $143.00 price target.